Fusion Antibodies
Nicola Hamilton is an experienced professional in the field of biotechnology, currently serving as Operations Manager at Fusion Antibodies since July 2016. In this role, Nicola has held various positions including Team Leader for Protein Production and Transient Gene Expression, as well as Senior Scientist, overseeing daily work schedules, report writing, and training of junior staff. Earlier experience includes a position as a Scientist in the Custom Biochip Unit at Randox from September 2015 to May 2016. Nicola holds a Bachelor's degree in Microbiology from Queen's University Belfast, completed in June 2015, and is skilled in routine cell culture maintenance and chemical methods of transient transfection.
This person is not in any teams
Fusion Antibodies
Since 2001, Fusion Antibodies has been dedicated to the discovery and early development of antibodies to help bring about a positive change in the healthcare industry. We offer a complete range of antibody-related services in Discovery, Engineering and Supply and have guided hundreds of projects through critical preclinical stages. Fifteen of our client’s projects have advanced to clinical stages, some as far as Phase II. We deliver a superior service for the development of antibodies by beginning each project with the end in mind. Our scientists are experts in early stage discovery of biologics. We offer this personalised service because we know that investment at the early stages saves not only millions of dollars but also months, even years of time, on projects that go awry at later stages of development. Through our vast experience we have developed a number of our own proprietary platforms for Antibody Humanization (CRX™), Affinity Maturation (RAMP™) and Developability optimisation (ADD™). Fusion Antibodies is a publicly held company, trading on the London Stock Exchange (LSE FAB.L) with headquarters in Belfast, Northern Ireland.